Prevent concomitant usage of tucatinib with CYP3A substrates, in which negligible concentration adjustments could bring on critical or lifetime-threatening toxicities. If unavoidable, lessen CYP3A substrate dose Based on solution labeling.4 mg/kg/working day] or bigger on mg/m2 foundation) Cleft palate and exencephaly are the commonest and continua